Silengenics · Confidential
SIG-001
· Product Overview
First-in-class RNA therapy silencing liver lipid disease at its source — dual cardiovascular and MASH benefit, from F1.
Enter
Incorrect password
SIG-001 · Silengenics
▶ Play
CONFIDENTIAL · FOR QUALIFIED INVESTORS ONLY
This presentation contains forward-looking statements based on management estimates. Not for distribution. © Silengenics 2026. All rights reserved.
1 / 3
‹
›